Tarsus Pharmaceuticals, Inc. Ratios

Ratios Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Profitability
Gross Margin 96.36%96.30%90.87%92.99%
EBT Margin -24.15%-240.53%-778.89%-63.16%
EBIT Margin -21.32%-242.92%-820.53%-65.90%
EBITDA Margin -24.25%-240.80%-778.48%-63.06%
Operating Margin -21.32%-242.92%-820.53%-65.90%
Net Margin -24.25%-240.51%-778.89%-63.16%
FCF Margin 5.54%-191.88%-682.04%-46.24%
Efficiency
Inventory Average 2.86M
Assets Average 175.44M203.38M246.68M321.24M
Equity Average 166.35M179.81M194.94M210.76M
Invested Capital 165.98M166.73M212.33M226.81M296.38M
Asset Utilization Ratio 0.330.130.070.57
Leverage & Solvency
Interest Coverage Ratio -28.52-42.78-15.36
Debt to Equity 0.100.150.32
Debt Ratio 0.090.110.19
Equity Ratio 0.970.930.850.740.60
Times Interest Earned -28.52-42.78-15.36
Valuation
Enterprise Value 671.69M293.42M173.99M442.93M1,825.25M
Market Capitalization 839.84M465.23M391.01M670.37M2,116.63M
Return Ratios
Return on Sales -0.24%-2.41%-7.79%-0.63%
Return on Capital Employed -0.07%-0.33%-0.68%-0.50%
Return on Invested Capital -0.33%
Return on Assets -0.08%-0.31%-0.55%-0.36%
Return on Equity -0.08%-0.35%-0.70%-0.55%